LPC
TVTX icon

Lion Point Capital’s Travere Therapeutics TVTX Stock Holding History

Lion Point Capital’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-78,000
Closed -$601K – 32
2024
Q1 		$601K Hold
78,000
– – 0.34% 23
2023
Q4 		$701K Hold
78,000
– – 0.35% 18
2023
Q3 		$697K Buy
+78,000
New +$1.1M 0.31% 20

Other funds holding TVTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Lion Point Capital's TVTX Position: Q2 2024 in Review

Lion Point Capital sold out of Travere Therapeutics (TVTX) in Q2 2024, closing a stake of 78,000 shares — an estimated $601K sold.

Lion Point Capital first reported a position in TVTX in Q3 2023 and held it in 3 quarters. The position peaked at $701K in Q4 2023. 174 funds tracked by Wall St. Rank hold TVTX as of Q2 2024.

  • Lion Point Capital reported no remaining Travere Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Lion Point Capital sold 78,000 Travere Therapeutics shares in Q2 2024, an estimated $601K.
  • Lion Point Capital first reported a position in Travere Therapeutics in Q3 2023 and held it in 3 quarters.
  • Lion Point Capital's Travere Therapeutics position peaked at $701K in Q4 2023.
  • 174 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2024.

Based on Lion Point Capital's 13F filing for Q2 2024, filed 14 Aug 2024.